Symbiomix Therapeutics' Series A - II Round

Symbiomix Therapeutics raised a round of funding on May 06, 2015.

Symbiomix is a held biopharmaceutical company with a focus on women's health. The company's lead product, SYM-1219, is a new anti-infective drug being studied as the first oral one-and-done treatment …

Articles about Symbiomix Therapeutics' Series A - II Round: